BioSpace News Archive

enGene Holdings Inc. today announced that Jason Hanson, Chief Executive Officer, will present a corporate overview at the Jefferies Global Healthcare Conference in New York City, on June 5, 2024, at 12:30 p.m. ET.

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC).

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced its participation in the Jefferies Healthcare Conference in New York on June 5-6, 2024.

BioNTech SE and the Coalition for Epidemic Preparedness Innovations are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem.

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 11:00 a.m. ET in New York, NY.

KALA BIO, Inc. announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET.

Black Diamond Therapeutics, Inc. announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY.

Bluejay Therapeutics announced that the European Medicines Agency has issued a positive opinion on the Company’s application for orphan designation for BJT-778 for the treatment of chronic hepatitis D.

Lipella Pharmaceuticals Inc. announces an abstract publication at the 2024 American Society of Clinical Oncology annual meeting, taking place from May 31 - June 4 in Chicago, IL, and online.